The US just has a lot of venture capital money running around. It's common for biotech companies to raise about as much as Character.ai (although typically at lower valuations) and then never end up launching a successful product. From a societal perspective, it's valuable to be able to search the space of long shots; from a funder's perspective, the rewards of a good investment are high enough to pay for a lot of bad ones.